[Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
The aim of our study was to estimate of phenazone oxidation and sulfadimidine acetylation in patients with Hodgkins disease, non Hodgkins lymphoma and acute leukemia. We observed increase in liver microsomal enzyme activity and predominance of the rapid acetylator phenotype in these pathological states. It should be taken into account when dosing drugs which are metabolized as markers of the liver metabolic efficiency like phenazone and sulphadimidine. One can also expect these patients to have a genetic predisposition to the development of cancer disease.
Wiela-Hojeńska
A
A
Katedry i Zakładu Farmakologii, Klinicznej Akadmii Medycznej, Wrocław.
Milejski
P
P
Orzechowska-Juzwenko
K
K
Usnarska-Zubkiewicz
L
L
Urbaniak-Kujda
D
D
Kotlarek-Haus
S
S
D000107:Acetylation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000378:metabolism*; D004198:Disease Susceptibility; D005260:Female; D006689:Hodgkin Disease / Q000378:metabolism*; D006801:Humans; D007938:Leukemia / Q000378:metabolism*; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D008875:Middle Aged; D010084:Oxidation-Reduction; D010641:Phenotype; D013418:Sulfamethazine / Q000378:metabolism*
D013418:Sulfamethazine; D000983:Antipyrine